Navigation Links
One Million Boxes of Over-the-Counter Smoking Cessation Products Sold in January 2008

More than 10 years of proven safety with NicoDerm(R) CQ(R), Nicorette(R)

and Commit(R)

PITTSBURGH, Feb. 4 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) Consumer Healthcare today announced that it sold one million boxes of smoking cessation products in January 2008, which includes NicoDerm CQ patches, Nicorette gum, and Commit lozenges. The New Year is the most popular time for smokers to try and quit, unfortunately, many of them fail without the proper tools and support. With more than 44 million smokers in this country, people need as many safe and effective options as possible to help them quit.

Therapeutic nicotine products, including NicoDerm CQ, can double a smoker's chances of quitting and remain smoke-free long-term (6 months and longer). In fact, 45 percent of smokers using NicoDerm CQ were smoke-free at the end of 10 weeks (vs. 18% on placebo, based on a study employing a group and individual behavioral support programs).

NicoDerm CQ allows smokers to wean off nicotine gradually and safely. The product is formulated with a patented SmartControl technology to control the release of nicotine and help target cravings. Smokers often experience withdrawal symptoms, such as irritability, mood depression, and nervousness, as well as nicotine cravings, when they abruptly quit smoking. The FDA- approved labeling for NicoDerm CQ and other therapeutic nicotine products states that it reduces these withdrawal symptoms. SmartControl technology ensures that a smoker receive a steady flow of nicotine for 16 or 24 hours (depending on how long a smoker wears the NicoDerm CQ patch). This means the smoker has a continuous defense to fight the nicotine cravings.

Since 1996, GlaxoSmithKline Consumer Healthcare's family of over-the- counter smoking cessation products, NicoDerm CQ patch, Nicorette gum and Commit lozenge, and personalized counseling and support resources have helped more than five million smokers quit smoking. Data from more than 100 clinical trials among more than 35,000 people have established the safety and efficacy profile of therapeutic nicotine for successful smoking cessation. These products are available without a doctor's prescription, in flexible dosing options at more than 35,000 retail outlets across the country.

"We are thrilled to see so many people trying to get their new year started in a healthy way by quitting smoking. But we know for some people, this is not an easy addiction to break, and we want to remind them of the safe options to wean them off of nicotine -- like NicoDerm CQ -- which are easily available to help support their quit attempts," said Bill Slivka, Vice President Smoking Control, GlaxoSmithKline Consumer Healthcare.

To encourage people to quit smoking for the rest of 2008, GSK Consumer Healthcare is offering a free NicoDerm CQ placebo patch or a 20-count box of Nicorette Cinnamon Surge to consumers. The placebo patch is available online at It is intended to show smokers that the NicoDerm CQ patch is easy to use, comfortable and discrete. Nicorette gum is available by calling 1-800-NICORETTE. These offers will help smokers decide whether NicoDerm CQ or Nicorette is the right option for their quit attempt.

Quitting smoking is the most important step smokers can take to improve their health -- and it's also one of the most difficult. By developing innovative new products and support systems to improve the quit experience, GSK Consumer Healthcare is working to inspire and enable every smoker to quit.

About NicoDerm CQ

NicoDerm CQ is the best-selling smoking cessation patch in history and has helped millions of smokers quit. It is also the number one doctor-recommended patch to quit smoking. When used as directed, NicoDerm CQ allows a smoker to gradually adjust to having less nicotine until eventually he doesn't need any at all. NicoDerm CQ step-down therapy is available in three strengths, 7mg, 14mg and 21 mg.

About GlaxoSmithKline Consumer Healthcare

GSK Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. Its more than 30 well-known brands include the leading smoking cessation products, Nicorette(R), NicoDerm(R) CQ(R) and Commit(R) as well as many medicine cabinet staples, including Abreva(R), Aquafresh(R), Sensodyne,(R) Tums(R) and Breathe Right(R).

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit:

SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. R Baby Foundation Raises $2.5 Million in First Year
2. PEAK Surgical, Inc. Closes $21 Million Series C Financing
3. China Sky One Medical Raises $25 Million in Private Placement
4. MediPurpose Sells 500 Millionth Safety Lancet to IMCO Member MMS Medical
5. Michael J. Fox Foundation awards up to $3 million to industry teams
6. Pennsylvania Governor Rendell Announces $1.8 Million Investment to Add Nurses, Improve Nurse Education Grants Awarded to Recipients in 28 Counties
7. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
8. Examination by National Expert Shows Blue Cross Blue Shield of Michigans Social Mission Contributions Totaled at Least $391 Million in 2007
9. Delray Beach Mayor Commemorates Diagnostic Centers of America (DCA) $2 Million Purchase from Siemens to Become Only Medical Facility in South Florida with Worlds Most Advanced Cardiac Scanner.
10. Helios Education Foundation Invests $6.5 Million in New Partnership with TGen
11. The Highmark Foundation Awards $4 Million in Highmark Healthy High 5 Grants to Two Nonprofit Organizations
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Association meeting in Washington D.C. revolved around the fact that proper dental care, both ... talk stressed the link between periodontal disease (more commonly referred to as gum disease) ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... way that they are handling security in light of the recent terrorist attacks in ... an attempt to stop an attack from reaching U.S. soil. Especially around special events ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, I ... Hillside, N.J. "Many people catch diseases simply from sitting on such dirty toilet ... protected from germs." , He developed the patent-pending QUDRATECS to eliminate the need ...
(Date:11/27/2015)... ... , ... The print component of “Supporting Our Caregivers” is ... York, Minneapolis, South Florida, with a circulation of approximately 250,000 copies and an ... social media strategy and across a network of top news sites and partner ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
Breaking Medicine Technology: